Otsuka reports phase 3 Voyxact data in IgA nephropathy
CURRENT BRIEF VERSION: Otsuka Pharmaceutical said new phase 3 VISIONARY data for Voyxact (sibeprenlimab-szsi) in IgA nephropathy showed a statistically significant, clinically meaningful reduction in proteinuria, reinforcing the evidence behind the company’s recently approved APRIL-targeting therapy. In the pivotal trial, adults with biopsy-confirmed IgA nephropathy receiving standard-of-care therapy were randomized to Voyxact 400 mg subcutaneously every four weeks or placebo; in the prespecified interim analysis, Voyxact cut 24-hour urine protein-to-creatinine ratio by about 50% at nine months versus a slight increase with placebo. The study enrolled about 510 patients, and Otsuka has said the blinded trial is continuing to assess kidney function decline over roughly 24 months using eGFR, the key confirmatory outcome for long-term benefit. Otsuka is also broadening its broader pipeline beyond nephrology: the company recently agreed, through Otsuka America, to acquire Transcend Therapeutics for about $1.225 billion, including $700 million upfront and up to about $525 million in sales milestones, adding TSND-201 (methylone), a phase 3 PTSD candidate, with closing expected in Q2 2026. (otsuka.co.jp)
Why it matters: While this is a human medicine story, it’s relevant to veterinary professionals who track translational nephrology, immune-mediated renal disease, and the growing use of pathway-specific biologics. Voyxact already received FDA accelerated approval in November 2025 to reduce proteinuria in adults with primary IgA nephropathy at risk for progression, with that decision tied to the same VISIONARY proteinuria data and with confirmatory renal outcomes still pending. The mechanism, selective APRIL inhibition, puts Voyxact into a fast-evolving IgA nephropathy market that also includes other recently approved targeted therapies, underscoring how renal immunology is moving toward earlier, mechanism-based intervention rather than broad immunosuppression alone. Otsuka’s separate move to buy Transcend also signals that the company is actively deploying capital across specialty areas, not just renal disease, as it builds out a wider late-stage pipeline. (fda.gov)
What to watch: The main next step is the VISIONARY readout on eGFR slope and other renal outcomes, which will help determine whether Voyxact’s early proteinuria benefit translates into durable kidney protection and supports full regulatory conversion. Separately, Otsuka’s planned Transcend acquisition is expected to close in Q2 2026 and would bring in a phase 3 PTSD asset plus follow-on prodrug work aimed at improving efficacy, safety, and tolerability. (otsuka.co.jp)